Copyright
©The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Aug 21, 2015; 21(31): 9297-9316
Published online Aug 21, 2015. doi: 10.3748/wjg.v21.i31.9297
Published online Aug 21, 2015. doi: 10.3748/wjg.v21.i31.9297
Perspectives in the treatment of pancreatic adenocarcinoma
Angel Cid-Arregui, German Cancer Research Center, Translational Immunology, Tumor Immunology Program, 69120 Heidelberg, Germany
Victoria Juarez, AsteriaPharma GmbH, 68723 Oftersheim, Germany
Author contributions: Cid-Arregui A analyzed the data, organized, designed and wrote the paper; Juarez V analyzed and organized the data and wrote the paper.
Conflict-of-interest statement: No conflict of interest exists regarding this paper. VJ is CEO of AsteriaPharma.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Angel Cid-Arregui, MD, PhD, German Cancer Research Center, Translational Immunology, Tumor Immunology Program, Im Neuenheimer Feld 280, 69120 Heidelberg, Germany. a.cid@dkfz.de
Telephone: +49-622-1423714
Received: February 3, 2015
Peer-review started: February 5, 2015
First decision: April 24, 2015
Revised: May 12, 2015
Accepted: July 18, 2015
Article in press: July 18, 2015
Published online: August 21, 2015
Peer-review started: February 5, 2015
First decision: April 24, 2015
Revised: May 12, 2015
Accepted: July 18, 2015
Article in press: July 18, 2015
Published online: August 21, 2015
Core Tip
Core tip: Pancreatic adenocarcinoma is a life threatening, fast evolving disease for which there is no cure. Recently, new chemotherapy regimens have shown significant improvement in survival in patients with advanced disease, opening a way for further progress. New therapeutic strategies based on targeted inhibitors or immunotherapy approaches, in particular antibody and adoptive T cell therapies, are getting growing attention as they are proving beneficial in pre-clinical and early phase clinical studies in combination with chemotherapy. Progress in understanding pancreatic tumor genetics, epigenetics and metabolism is providing new biomarkers that may be of value in early detection and progression assessments.